QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
A new treatment called low- intensity shockwave therapy is being promoted for erectile dysfunction in the US. This therapy, similar to that used for kidney stones, is not approved by the FDA for this use. The usual treatments for…
Recommendation by urologist was the strongest determinate for AS decision. More than half of newly diagnosed patients with low-risk prostate cancer chose active surveillance (AS) with the recommendation from a urologist being the strongest determinant, according to a recent study…
A systematic review and meta-analysis This study investigated the impact of exercise on the quality of life (QoL) and metabolic health in men diagnosed with prostate cancer. The study, which included 33 randomized controlled trials with 2567 participants, found that…
Dr. Catalona conceived the Prostate Cancer Active Surveillance Project (PCASP) in 2016, shortly after the American Urological Association (AUA) launched its AQUA Registry to assist urologists in complying with the federal government’s requirement for physicians to report their outcomes…
Implementation science, a burgeoning field in public health research is the study of methods to promote the adoption and integration of evidence- based best practices, interventions, and policies into routine healthcare and public health settings to improve health in the…
Indigestion due to gastro-esophageal reflux disease (“GERD” or “heartburn”) is caused by stomach acid refluxing into the esophagus. Omeprazole is a commonly-used pill that is used to treat GERD by decreasing the production of stomach acid. However, a potential serious…
Howard Wolinsky (former medical editor at the Chicago Sun Times) has experience with active surveillance. He has “served” 13 years on active surveillance and is pondering whether to continue or to make a break for it. In a recent article…
The authors studied prostate cancer and its link to genetics. They wanted to see if men with a higher genetic risk of prostate cancer could lower their risk by living a healthy lifestyle. They followed 12,411 men for 27 months,…
A recent study presented at the European Society for Medical Oncology (ESMO) Congress in 2023 discussed a new treatment for patients with advanced prostate cancer. The research, led by Dr. William K. Kelly, examined the use of a treatment called…
Pathogenic germline mutations in certain genes can increase the risk of aggressive prostate cancer (PC). Researchers sought to find out how common these mutations are in men with low-risk PC who are under active surveillance. The authors also wanted to…
"*" indicates required fields
